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Abstract We present the discovery of a nano-sized pro-
tein-derived micellar drug delivery system based on the
polycationic albumin precursor protein cBSA-147. The
anticancer drug doxorubicin (DOX) was efficiently encap-
sulated into nanosized micelles based on hydrophobic
interactions with the polypeptide scaffold. These micelles
revealed attractive stabilities in various physiological buf-
fers and a wide pH range as well as very efficient uptake into
A549 cells after 1 h incubation time only. In vitro cytotox-
icity was five-times increased compared to free DOX also
indicating efficient intracellular drug release. In addition,
multiple functional groups are available for further chemical
modifications. Based on the hydrophobic loading mecha-
nism, various classical anti-cancer drugs, in principle, could
be delivered even synergistically in a single micelle. Con-
sidering these aspects, this denatured albumin-based drug
delivery system represents a highly attractive platform for
nanomedicine approaches towards cancer therapy.
1 Introduction
Nanomedicine has emerged as an innovative strategy for
cancer therapy with great promise for clinical applications
[1]. Nanomedical approaches to drug delivery involve the
development of nanoscale particles or macromolecules to
improve the biological activity and pharmacokinetic profile
of drug candidates [1]. In particular, small-molecule che-
motherapeutics often elicit severe side effects, such as
anemia, vomiting, diarrhea, decreased immunity and alo-
pecia, which is due to the systemic distribution of cytotoxic
drugs [2]. In recent years, a large number of natural and
synthetic macromolecules as well as inorganic particles
have been developed as drug delivery nanocarriers [3],
such as liposomes [4–6], polymeric nanoparticles [7, 8],
inorganic nanoparticles [9] as well as proteins [10–13]. The
long systemic circulation times of nano-sized drugs and
drug carriers and the increased vascular permeability of
tumor tissue leads to an accumulation at tumor sites, which
is often referred to as passive targeting or ‘‘enhanced per-
meability and retention effect’’ (EPR effect) [14, 15]. As a
particular feature, such nano-sized drug delivery systems
could serve as platform to integrate multiple additional
functionalities such as specific targeting ligands or probes
suitable for tumor imaging [16, 17]. Still, there are major
challenges associated to the design of an ideal macromo-
lecular drug delivery system [2, 3]. In order to reduce drug-
unrelated side-effects in humans, biocompatibility of the
entire drug delivery complex represents a key concern to
achieve a suitable therapeutic window. In addition, the
prevention of drug leakage during blood circulation on the
one hand but achieving efficient drug release at target cells
on the other hand represent crucial factors that still appear
challenging to achieve. Other prerequisites include efficient
permeability through vascular barriers and cell membranes,
This article is part of the Topical Collection ‘‘In Focus:
Nanomedicine’’.
Y. Wu  T. Weil (&)
Institute of Organic Chemistry III, Macromolecular Chemistry,
Albert-Einstein-Allee 11, 89081 Ulm, Germany
e-mail: Tanja.Weil@uni-ulm.de
Y. Wu  E. K. Shih  T. Weil
Department of Chemistry, National University of Singapore,
3 Science Drive 3, Singapore 117543, Singapore
A. Ramanathan  S. Vasudevan
Duke-NUS Graduate Medical School,




great specificity for tumor tissue, high loading of the drug
cargo as well as fast degradation of the entire carrier sys-
tem after delivery producing non-toxic metabolites. In view
of these criteria, it is not astonishing that only few drug
delivery systems have entered clinical trials yet.
Doxorubicin (DOX) represents a potent cytotoxic drug
that has been applied to address a broad number of dif-
ferent kinds of cancers [18, 19]. It consists of an anthra-
cycline antibiotic DNA intercalator inhibiting DNA
replication, which has been successfully applied in cancer
chemotherapy [18, 19]. For solubility reasons, DOX needs
to be administered intravenously as hydrochloride salt,
which limits its cellular uptake and cardiac toxicity due to
unspecific cell uptake represents a serious side-effect [20].
Therefore, liposome formulations such as DoxilTM con-
taining DOX have entered the market [21]. However,
inherent limitations of liposomes such as drug leakage into
the plasma and vascular capillaries still leaves room for
improvement [22, 23]. In addition, dendrimers have been
applied successfully for the complexation of DOX [24].
Dendrimer mediated complexation is advantageous in
terms of stability, controlled release, drug payload and
reduced toxicity of the entrapped drug(s) [25]. However,
even though studies on non-covalent interactions of den-
drimers with drugs suggest improved drug solubilization,
low numbers of encapsulated drug molecules and limited
complex stabilities represent key concerns [25].
Protein-based drug delivery systems have emerged
recently since they consist of ‘‘natural’’, non-toxic mono-
mers, they reveal low cytotoxicity and particularly human
serum albumin (HSA) is known to exhibit insignificant
immunogenicity [11]. HSA is a well-known transportation
protein ubiquitous in the blood plasma to allow the delivery
of hydrophobic nutrients [26]. Utilizing its native trans-
portation mechanism, albumin formulated cancer drugs,
such as AbraxaneTM (albumin formulated paclitaxel for
treating breast cancer), have been successfully introduced to
the market and show higher efficiencies in patients without
prominent side-effects such as allergic reactions [27–29].
However, in general, protein-based delivery platforms also
bear several draw-backs such as their low membrane per-
meability, immunogenicity and low metabolic stability.
Herein, we disclose a novel type of denatured albumin-
based copolymer that facilitates encapsulating hydrophobic
drug molecules thus forming nano-sized, stable micelles
that are able to efficiently pass cell membranes. Recently,
protein-derived copolymers were introduced, consisting a
polypeptide backbone and several grafted, hydrophilic
polyethylene(oxide) (PEO) side chains (Wu et al., in prep-
aration, [30–32]). PEO side-chains are known to reduce
non-specific interactions as well as immunogenicity and
antigenicity of proteins and peptides. The promising appli-
cations of such copolymers include surface patterning
(Wu et al., in preparation), nanoparticles coating [30], gene
delivery [31] as well as targeted delivery of hydrophobic
molecules into cancer cells [32]. Such biohybrid micelles
represent a novel type of delivery platform offering great
potential to effectively transport and release lipophilic
drugs into cancer cells.
2 Experimental
2.1 Materials
Albumins from bovine serum (BSA) (C98%, Sigma
Aldrich), O-(2-maleimidoethyl)-O0-methyl-polyethylene
glycol 5000 (PEG-5000-MI) ([90% NMR, Aldrich), prop-
argylamine (98%, Aldrich), maleic anhydride (C99.0%,
Fluka), glacial acetic acid (ACS 99.7%, Alfa Aesar),
N-hydroxysuccinimide (98%, Aldrich), tris(2-carboxy-
ethyl)phosphine hydrochloride (TCEP) (98%, Alfa Aesar),
Urea (98?%, Alfa Aesar), ethylenediaminetetraacetic acid
(EDTA) (99%, Alfa Aesar) and TrizmaTM base (BioUltra,
C99.8%, Sigma), doxorubicin hydrochloride salt (DOX)
(C99.0%, XingCheng ChemPhar Co. LTD, China) were
used as received without further purification. Bio-Rad Bio-
Gel P30 was used for desalting, vivaspin ultrafiltration tubes
were purchased from GE healthcare for purification. Dul-
becco’s Modified Eagle Medium (DMEM) (1X) liquid (high
glucose), Fetal Bovine Serum (FBS) Standard Quality (EU
approved), penicillin/streptomycin solution (1009) were
purchased from PAA Laboratories GmbH, MEM
[non-essential amino acids solution 10 mM (1009)] was
purchased from Invitrogen.
2.2 Synthesis of N-Propargyl Maleimide
Maleic anhydride (980 mg, 10 mmol) was reacted with
propargylamine (550 mg, 10 mmol) in 20 mL glacial acetic
acid at room temperature (RT) overnight. Then, sodium
acetate (164 mg, 2 mmol) and acetic anhydride (10 mL)
were added and the reaction mixture was heated to 65C for
2 h. After reaction, all solvent was removed under vacuum
and the residue was purified by silica gel column chroma-
tography (EtOAc:Hexane 1:3) to yield 60 mg of a white solid
(yield 5%). Rf 0.56 (EtOAc/heptane, 1:1 v/v), 1H NMR
(CDCl3, 300 MHz): d 6.75 (s, 2H), 4.28 (d, 2H, J 1.8 Hz,);
2.20 (t, 1H, J 1.8 Hz); 13C NMR (CDCl3, 300 MHz): d 169.2,
134.4, 76.9, 71.5, 26.8. MS–ESI, 136 M?.
2.3 Preparation of cBSA-147-PEO(5000)28 (2)
dcBSA-147-PEO(5000)28 (2) was prepared using a similar
procedure reported in our previous paper [30]. Briefly,
cationic bovine serum albumin, cBSA-147 [33] (1, 10 mg,
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0.15 lmol) was first denatured in degassed urea-phosphate
buffer (10 mL, 10 mM phosphate buffer, 5 M urea and
2 mM EDTA, pH 7.4) for 10 min, and then reducing agent
TCEP (4.3 mg, 15 lmol) was added under argon atmo-
sphere for 30 min. Subsequently, PEG-5000-MI (77 mg,
15 lmol) was added to the reaction and stir at RT for 3 h.
Finally, the capping reagent N-propargyl maleimide
(30 lmol) was given to the reaction and stir for another
3 h. The reaction mixture was first purified by ultrafiltra-
tion with Tris–HCl buffer (20 mM Tris, 150 mM NaCl,
2 mM EDTA, pH 7.4), and followed by further size
exclusion purification using HiPrepTM SephacylTM S-100
HR gel filtration column on AKTA¨ Purifier flash protein
liquid chromatography with Tris–HCl buffer (20 mM Tris,
150 mM NaCl, pH 7.4). Then, the purified material was
desalted and lyophilized to yield dcBSA-147-PEO(5000)28
(2) as white fluffy solid. The product was characterized by
gel electrophoresis using precast NuPAGE TA 3–8% Gel
(Invitrogen) in NovekTM Mini-Cell.
2.4 Preparation of dcBSA-147-PEO(5000)28
Micelle (3)
DOX hydrochloride (DOX 9 HCl) (4 mg, 7 mmol) was
dissolved in 500 lL deionized-distilled water and mixed
with 1.2 equivalents of triethylamine (1.2 lL, 8.4 mmol).
The aqueous solution was extracted five times with
dichloromethane. The combined organic extracts were
evaporated in vacuum and 3 mg of DOX were obtained.
This DOX stock solution was prepared by dissolving the
obtained solid in 500 lL of DMF to achieve a total con-
centration of 6 mg/mL. dcBSA-147-PEO(5000)28 (2)
(0.5 mg, 0.0028 lmol) in distilled-deionized water was
combined with the desired molar ratios of DOX, (ratios of
1:1, 1:5, 1:10, 1:20, 1:50, 1:100) and allowed to stir
overnight in the dark at RT. The reaction mixtures were
transferred to 3.5 K MWCO Slide-A-Lyzer MINI Dialysis
cassettes (Pierce) and dialyzed in 1 L distilled-deionized
water for 24 h at 4C; during this time period, water was
exchanged 3–5 times. The amount of entrapped DOX in
each molar ratio was determined by measuring the absor-
bance at 488 nm using Tecan M-1000 microplate reader.
2.5 Negative Staining Transmission Electron
Microscopy
The morphology of dcBSA-147-PEO(5000)28-(DOX)14
micelles was characterized via TEM applying the negative
staining technique. A drop of 1 mg/mL dcBSA-147-
PEO(5000)28-(DOX)14, dissolved in an aqueous solution
was deposited onto a hydrophilic copper grid with a carbon
film for approximately 1 min and then blotted excess of the
sample by filter paper. The grid was allowed to dry at RT
for overnight and then stained with 1% Uranyl acetate
solution for TEM investigations.
2.6 Dynamic Light Scattering
The hydrodynamic size distribution of dcBSA-147-
PEO(5000)28-(DOX)14 micelles was characterized by
DLS using a Malvern Nanosizer (Malvern Ltd, Malvern,
UK). dcBSA-147-PEO(5000)28-(DOX)14 was prepared at
0.15 mg/mL concentration in aqueous solution and filtered
through 0.2 lm microsyringe filter before measurement to
avoid dust contamination. Autocorrelation functions were
analyzed by cumulants method and COTIN routine to esti-
mate hydrodynamic diameter. The hydrodynamic diameter
distribution was presented as number distribution.
2.7 Characterization of Micelle Stability in Various
Media
100 lL aliquots of 0.1 mg dcBSA-147-PEO(5000)28-
(DOX)14 samples were dialyzed using 3.5 K MWCO Slide-A-
Lyzer MINI Dialysis devices (Pierce) in 10 mM pH 3 and 5
citrate buffer and 10 mM (pH 7 and 9) and Tris buffer,
respectively, for 2 days and the absorbance spectra were
recorded before and after dialysis.
2.8 Cell Culture
Hela cells (human cervix carcinomic cell line) and A549
cells (carcinomic human alveolar basal epithelial cell line)
were obtained from DSMZ (German Collection of Micro-
organisms and Cell Cultures, Braunschweig) and cultured
in DMEM medium with high glucose supplemented and
with 10% fetal bovine serum (FBS), 100 U/mL Penicillin,
0.1 mg/mL Streptomycin, 0.1 mM non-essential amino
acids at 37C in a humidified 5% CO2 incubator.
2.9 Cytotoxicity Assay
HeLa cells were plated into a white 96 well microplate at
a density of 8000 cells per well and incubated overnight
for attachment. After incubation, the media from each
well were aspirated and exchanged with 100 lL of fresh
DMEM medium and the desired amount of either free
DOX or dcBSA-147-PEO(5000)28-(DOX)14 micelles. All
concentrations were prepared as triplicates. After further
incubation with drug molecules for 12, 24 and 48 h, cell
viability was tested by Cell-titer-GloTM (Promega) cell
viability assay kit according to manufactory’s instruction.
Cells that were not treated with any drug were considered
as blank. The IC50 values and the 50% inhibitory con-
centrations were obtained through GraphPad Prism 3
software.
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2.10 Live Cell Imaging of Intracellular DOX
in A549 Cells
A549 cells were plated onto glass cover slips and incubated
for 12 h to allow cell attachment and spreading. Thereafter,
0.1 lM of either free DOX or dcBSA-147-PEO(5000)28-
(DOX)14 micelles were added to the cells and incubated
for one additional hour. The cells were then washed 3 times
with PBS, replaced with fresh medium and incubated with
5 lg/ml of WGA-Alexa Fluor 594 conjugate (Cat #
W11262, Invitrogen) for 10 min to label the cell membrane
and imaged without further washing. Microscopy was
performed with a Zeiss LSM 710 META laser scanning
microscope fitted with Argon, HeNe543 and Diode405-30
lasers. Z-sections of chosen field were acquired with a 409
oil immersion objective (Zeiss, Germany). Excitation and
emission wavelengths of 535–562 nm for DOX and of
600–620 nm for WGA-Alexa Fluor 594 detection were
selected. The acquired images were processed with Zen
software developed by Carl Zeiss.
2.11 Quantification of DOX Uptake
For the quantification of DOX cell uptake, images obtained
from five different sections in each of the slides were
analyzed using the public domain NIH ImageJ pro-
gram with default settings (developed at the US National
Institutes of Health and available on the Internet at
http://rsb.info.nih.gov/nih-image/). To calculate the per-
centage of intracellular DOX, the fluorescence intensity of
DOX [green] was divided by the total fluorescence (DOX
[green] and the cell membrane [red]) and multiplied by
100.
3 Results and Discussion
3.1 Preparation and Characterization
of dcBSA-147-PEO(5000)28 DOX Micelles
Polycationic bovine serum albumin (cBSA-147) was used
as precursor protein for the preparation of the PEO-grafted
copolymer dcBSA-147-PEO(5000)28 (2). cBSA-147 stands
for cationic BSA, which was obtained after converting
about 87 out of 100 carboxylic acid groups of aspartic and
glutamic acid residues of native BSA into primary amino
groups according to published procedures [33]. cBSA-147
serves as efficient gene delivery carrier of low cytotoxicity
that reveals fast and efficient cell uptake and even allows
stable gene transfections [33] and it has been applied
successfully as biocompatible surface coating [34]. How-
ever, due to the potential immunogenicity of cationic
albumin derivatives [35], further modifications are required
to efficiently shield epitopes to allow multiple dose appli-
cations in vivo. Therefore, cBSA-147 was converted into a
polypeptide single chain copolymer (2) under controlled
denaturing conditions (5 M urea) and the presence of the
mild reduction agent TCEP to destabilize the globular
architecture of BSA and reduce all 17 disulfide bridges
(Fig. 1). The denatured protein backbone was stabilized in
situ by applying long, hydrophilic polyethyleneoxide
(PEO-5000) side chains carrying a single thiol-reactive
maleimide group yielding the PEO grafted copolymer
dcBSA-147-PEO(5000)28 in one reaction step. To con-
tribute to the clarity of the nomenclature, dcBSA-147-
PEO(5000)28 denotes denatured cationic BSA-147 [31]
carrying about 28 grafted PEO-5000 chains with a
molecular weight of 5,000 g/mol. Thereafter, N-propargyl
(1) (2) (3)
BSA cBSA-147 dcBSA-147-PEO(5000)28 dcBSA-147-PEO(5000)28-DOX
EDC










⇒Copolymer to allow micelle formation
Micelle formation
⇒DOX loading
Fig. 1 Preparation of dcBSA-147-PEO(5000)28-DOX micelles
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maleimide was added to cap all remaining free thiol groups
that have not reacted with the PEO chains for steric rea-
sons. This capping step is essential and significantly
improves the shelf life the denatured PEO-grafted
copolymers [30]. In addition, the N-propargyl moiety fur-
ther contributes to the lipophilicity of the polypeptide
backbone which is crucial for micelle formation in aqueous
solution. Denaturation of globular BSA exposes a large
number of functional groups along the backbone, which
were previously hidden inside the protein scaffold and
become available for further reactions. In addition, lipo-
philic amino acids originating from e.g. hydrophobic
pockets are now accessible and, together with the
N-propargyl groups, allow efficient interaction with
hydrophobic drug molecules. The presence of multiple
positive charges contribute to increased membrane
permeability and cellular uptake and the high number of
PEO side chains distributed along the backbone were
attached to reduce nonspecific adsorption and to minimize
immunogenicity. According to SDS-PAGE, dcBSA-147-
PEO(5000)28 (2) prepared herein possesses an approximate
molecular weight of about 200 kDa (Fig. 2a). Considering
the presence of multiple functional groups along the
polypeptide backbone corresponding to the peptide
sequence of BSA (by considering that most carboxylic
acids have been converted into amino groups), this grafted
polymer represents an attractive platform for conjugating
targeting ligands and other functional moieties.
Serum albumin transports water-insoluble lipids in the
bloodstream and about six hydrophobic ligands could be
transported [36]. After denaturation, the tertiary structure of
dcBSA-147-PEO(5000)28 has been destroyed but sufficient
numbers of lipophilic amino acids and additional N-prop-
argylamine are still present that could non-covalently inter-
act with hydrophobic molecules. DOX HCl was chosen as
model drug since it has been well characterized in vitro and in
vivo, it has a lipophilic scaffold and emits above 500 nm thus
facilitating characterization via fluorescence microscopy.
DOX loading was performed according to published proce-
dures [37]. Briefly, DOX hydrochloride salt was first neu-
tralized and extracted into a dichloromethane layer. The
obtained non-water soluble drug was then re-dissolved in a
minimum amount of dimethylformamide and added into
dcBSA-147-PEO(5000)28 (2, 1 mg/mL) dissolved in aque-
ous solution. After overnight stirring, micelles were purified
by dialysis. The purification efficiency was accessed by
loading DOX micelles (3) and free DOX HCl into Bio-Gel
P30 (Bio-Rad) size exclusion columns. Free DOX HCl is
indicated by a red colored narrow band, which remains on
top of the column, whereas sufficiently stable DOX micelles
quickly moved along the column and no traces of free DOX
were present on top of the column suggesting that all DOXs
were associated with the copolymer micelles (Fig. 2c).
3.2 Characterization of dcBSA-147-PEO(5000)28
DOX Micelles
In order to quantify the average number of encapsulated
DOX molecules as well as the maximum drug loading
efficiency of the micelle system, different equivalents of
DOX were applied for micelle preparation. After dialysis,
the absorbance spectra of the micelles were recorded
(Fig. 3a) and the characteristic DOX absorbance with a
maximum at 488 nm was observed indicating successful
DOX loading. The DOX concentration was calculated
considering a molar extinction coefficient of 11,500/M/cm
and the average number of DOX encapsulated in the
micelles is given in Table 1. DOX loading could be esti-
mated due to a linear correlation of the amount of DOX
added in access to the copolymer solution (feed DOX)
versus the number of encapsulated DOX molecules
(Fig. 3b). By adding 100 equivalent of DOX, a maximum
number of about 14 DOX molecules was reproducibly






Fig. 2 Characterization of
dcBSA-147-PEO(5000)28 (2)
and dcBSA-147-PEO(5000)28-
(DOX)14 micelles. a SDS-
PAGE of cBSA-147 (1) (line 1)
and dcBSA-147-PEO(5000)28
(2) (line 2); b agarose gel
electrophoresis of dcBSA-147-
PEO(5000)28-(DOX)14 micelles
in TAE buffer (Tris base–acetic
acid–EDTA buffer, pH 7.4);
c loading of DOX HCl and
dcBSA-147-PEO(5000)28-
(DOX)14 micelles onto a Bio-
gel P30 size exclusion column
using the same amount of eluent
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protein carrier HSA is only able to accommodate up to six
lipophilic guest molecules [36] thus indicating an increased
drug load after protein denaturation. The morphology and
size distribution of micelles containing about 14 DOX were
investigated by TEM with uranyl acetate staining. Very
homogenous micelles with narrow size-distributions were
observed by TEM. Their size with average diameters of
about 56 nm (Fig. 4a, b) is generally considered an ideal
size for passive targeting and accumulation into tumor
tissues by the ERP effect [14, 15]. The size distribution of
dcBSA-147-PEO(5000)28-(DOX)14 micelles in solution
was further investigated using DLS and narrowly dispersed
particles were found with average diameter of approxi-
mately 30 nm which is comparable with the particle size
found by TEM. In addition, DOX-containing micelles were
characterized by a highly positive surface charge origi-
nating from the cationic nature of the cBSA-147 precursor
protein, which was confirmed by gel electrophoresis
(Fig. 2b) and which ensures electrostatic interaction with
cellular membranes and cell uptake.
3.3 In Vitro Assessment of Micelle Stability
Undesired drug leakage in blood plasma represents a common
limitation for most drug deliver carriers, which is known
to cause several serious side effects. To study the stability of
(3) in different media, dcBSA-147-PEO(5000)28-(DOX)14
micelles containing about 14 DOX molecules were dialyzed
in PBS buffer as well as DMEM cell culture medium for
4 days. The absorbance spectra were recorded before and after
dialysis (Fig. 5a). It is noteworthy that no changes of the
absorbance occurred indicating high micelle stability under
high ion strength and cell culture conditions. Furthermore, the
stability of these micelles at different pH was also investi-
gated. Dialysis was performed in the physiological relevant
range from pH 3 to pH 9 for 2 days, and the absorbance spectra
of these micelles did not reveal any changes (Fig. 5b).
Therefore, the albumin-derived copolymer micelles display
remarkably high stabilities in solution and no drug leakage
was observed which is very critical for drug delivery appli-
cations and might contribute to an improved side effect pro-
file. The notably stability could attribute to multivalent
interactions of protein hydrophobic moieties with DOX
molecules, which is especially attractive comparing to the
liposome formulated DoxilTM using in the market.
3.4 Enhanced Cellular Uptake
The unfavorable cellular uptake efficiency of DOX is
known as one of the major limitations of DOX chemo-
therapy [20]. The stable encapsulation of DOX into posi-
tively charged albumin micelles should facilitate cellular
uptake via endocytosis pathways. Therefore, the cellular
uptake efficiency of dcBSA-147-PEO(5000)28-(DOX)14
micelles into A549 cells was followed by confocal
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Fig. 3 Loading of different ratio of DOX into dcBSA-147-
PEO(5000)28-(DOX)14 micelles (3). a Absorbance spectra of
dcBSA-147-PEO(5000)28-DOX for the same concentrations of (2)
but different concentrations of DOX loaded into dcBSA-147-
PEO(5000)28 micelles (3); b correlation of the ratio of added DOX
(feed DOX) versus (2) in solution and the amount of DOX loaded into
micelles (3)














1:1 0.5 ± 0.1 0.15 ± 0.03 51.6 ± 9.9
5:1 1.2 ± 0.1 0.34 ± 0.01 23.1 ± 1.0
10:1 1.8 ± 0.2 0.52 ± 0.07 17.2 ± 2.3
20:1 4.3 ± 0.8 1.22 ± 0.23 20.4 ± 3.9
50:1 8.2 ± 1.1 2.33 ± 0.31 15.5 ± 2.0
100:1 13.7 ± 2.2 3.91 ± 0.63 13.1 ± 2.1
a Molar ratio of feed DOX added versus dcBSA-147-PEO(5000)28
(2) for micelle formation
b Molar ratio of DOX loaded into dcBSA-147-PEO(5000)28 micelles
c Weight percentage of DOX loaded into dcBSA-147-PEO(5000)28
micelles
d Weight percentage of loaded DOX to added DOX (feed DOX)
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basal epithelial cells (A549 cells) were used to assess
cellular permeability into epithelial tissue. After 1 h only,
significantly increased cellular uptake of dcBSA-147-
PEO(5000)28-(DOX)14 at 0.1 lM concentration was
observed. In addition, free DOX hydrochloride salt of the
same concentration was applied in parallel as comparison.
As shown in Fig. 6, substantial amount of DOX (green
channel) was found in such cells treated with DOX micelle
(3), whereas considerably less emission intensity was col-
lected for such cells incubated with non-complexed, free
DOX molecules. The quantification of DOX uptake was
calculated based on these confocal micrographs (Fig. 7).
DOX micelles revealed more than 5 times higher uptake
efficiency compared to free DOX, which is also reflected







Fig. 4 a Negative staining

















30Fig. 5 Size distribution of
dcBSA-147-PEO(5000)28-







































































Fig. 6 a Absorbance spectra of dcBSA-147-PEO(5000)28-(DOX)14 micelles before and after dialysis in different physiological buffers;
b absorbance spectra of dcBSA-147-PEO(5000)28-(DOX)14 micelles before and after dialysis in different pH buffer solutions
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3.5 In Vitro Cytotoxicity of dcBSA-147-PEO(5000)28-
(DOX)14
Hela cells are considered the most common human carci-
nomic cell model used in cancer research. The cytotoxic
activity of dcBSA-147-PEO(5000)28-(DOX)14 micelles was
evaluated in Hela cells and compared with DOX hydro-
chloride salt. Hela cells were treated with a series of con-
centrations of dcBSA-147-PEO(5000)28-(DOX)14 or the
free drug DOX HCl for 12, 24 and 48 h and cell viability
at each concentration was tested by applying the Cell-Titer-
Glo cell viability assay (Promega) and plotted (Fig. 8). For
all 3 incubation times, dcBSA-147-PEO(5000)28-(DOX)14
exhibited an around five-times increased cytotoxicity com-
pared to the DOX hydrochloride salt. After 12 h of incuba-
tion, an IC50 value of the DOX micelles of about 1.1 ±
0.2 lM was found (free DOX: IC50 of 5.5 ± 0.7 lM), which
was further decreased down to 0.4 ± 0.01 (free DOX:
IC50 = 1.5 ± 0.3 lM) and 0.14 lM after 48 h of incuba-
tion, indicating in all cases a five-times increased cytotoxicity
of dcBSA-147-PEO(5000)28-(DOX)14 micelles compared
with free DOX HCl (Fig. 9). Extended observation times for
achieving the maximum biological activity have been
reported for other delivery systems as well [33] and are most
likely due to slower cell uptake and drug release inside the
cell. The attractive in vitro cytotoxic activity of dcBSA-147-
PEO(5000)28-(DOX)14 micelles could be attributed to their
high membrane permeability benefits from multiple positive
charges, as well as efficient carrier degradation and drug
release in lysosomes.
4 Summary and Conclusions
The efficient protein-derived drug delivery system dcBSA-
147-PEO(5000)28 (2) was prepared based on the polycationic
Fig. 7 Live confocal images of DOX in A549 cells. a DOX in
dcBSA-147-PEO(5000)28-(DOX)14 is delivered into the A549 cells,
top panel cells incubated with free DOX, bottom panel A549 cells
incubated with dcBSA-147-PEO(5000)28-(DOX)14. b Enlarged view
of a field (marked by a square) from panel A. Cell membrane (red



























Free DOX     dcBSA-147-PEO(5000)28-(DOX)14
Micelles
Fig. 8 Quantification of intracellular DOX in A549 cells after 1 h
incubation time
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albumin precursor protein BSA-147. This copolymer was
designed to encompass several important features such as (1)
positive charges to facilitate cellular uptake via endocytosis,
(2) a large number of hydrophilic and lipophilic groups along
the backbone facilitating the formation of nanosized micelles
of about 56 nm with narrow size distributions and high sta-
bility in different physiological buffers, cell media and a
broad pH range, (3) about 28 PEO chains along the backbone
to reduce plasma protein binding, immunogenicity and
contribute to high micelle stability in solution, (4) high
drug loading of about 14 lipophilic DOX molecules per
micelle. Due to the synergistic combination of all these fea-
tures, unique nanosized containers were achieved that are
attractive to efficiently encapsulate and stabilize lipophilic
molecules.
Cell imaging via confocal microscopy revealed fast cell
uptake of dcBSA-147-PEO(5000)28-(DOX)14 nanocon-
tainers after only 1 h of incubation time. DOX uptake after
encapsulation into micelles was fivefold increased com-
pared to free DOX. In vitro cytotoxicity experiments
revealed corresponding results since an about five-times
higher cytotoxicity of dcBSA-147-PEO(5000)28-(DOX)14
micelles compared to free DOX was found. The exact
mechanism of intracellular drug release is still unknown
and will be investigated in future studies. The drug delivery
system reported herein could in principle be used to
encapsulate a broad range of lipophilic drug molecules and
might therefore be attractive for combination therapy, e.g.
the application of different drugs acting via different modes
of action. In addition, the denatured protein backbone
provides multiple functional groups available for further
chemical modifications. In this way, a highly versatile and
attractive platform for anticancer drug delivery was
developed with great potential for in vivo studies.
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